Welcome! Login | Register
 

NEW: Milan Brown Fired As Holy Cross Basketball Coach—Holy Cross relieves Milan Brown of his coaching…

Holy Cross’s Season Ends After 90-83 Loss to Bucknell in OT—Holy Cross falls to Bucknell 90-83 in the…

Friday Financial Five – March 6, 2015—Bloomberg has a report on states opting to…

Finneran: MLK, LBJ and Savage Selma—Every white person in America should go see…

Holy Cross Visits Bucknell For Rd. 2 of Patriot League Tournament—Crusaders visit Bison for round 2 of the…

Leather Storrs: What’s in a Name?—“Hey Whitney, you seem a lot peppier, guess…

NEW: Vince Wilfork Releases Statement As Patriots Decline His Option—Patriots appear to be moving on from Vince…

Fairman Cowan Collegiate Lecture Series to be held at Becker College—Becker College will be hosting The Worcester Regional…

Where Will You WOO? - Week of March 5, 2015—Where will you WOO during the week of…

99 Restaurant and Pub Teams Up with Wachusett Brewery for Horseshoe Ale—Two iconic New England brands are coming together…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.